Stockreport

Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline [Yahoo! Finance]

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a $60 price target. The positive stance comes amid expectations that the company will deliver topline resu [Read more]